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Summary Angiogenesis is a recently described prognostic factor in non-small-cell lung cancer. Platelet-derived endothelial cell growth factor
(PD-ECGF), shown to be the enzyme thymidine phosphorylase (TP), induces angiogenesis in vitro and in vivo. High intracellular levels of the
enzyme are associated with increased chemosensitivity to pyrimidine antimetabolites. PD-ECGF/TP expression was evaluated immuno-
histochemically in surgically resected specimens from 107 patients with operable non-small-cell lung cancer using the P-GF.44C monoclonal
antibody. High expression of PD-ECGF/TP was found in 25% of cases and was associated with high vascular grade (P = 0.01). Fourteen
of 32 (44%) high vascular grade tumours showed a positive reactivity for PD-ECGF/TP vs 13/75 (17%) of low/medium vascular grade.
Positive expression was observed more frequently in T2-staged cases than in Ti (P = 0.04). While overall survival was not affected
(P = 0.09), subset analysis revealed that node-negative patients with positive PD-ECGF/TP expression had a worse prognosis (P= 0.04).
The results suggest that PD-ECGF/TP may be an important molecule involved in angiogenesis in non-small-cell lung cancer. Up-regulation of
the enzyme defines a more aggressive tumour phenotype in patients with node-negative disease. Assessment of vascular grade and PD-
ECGF/TP expression should be taken into account in the design of randomized trials assessing the role of adjuvant chemotherapy in non-
small-cell lung cancer.
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Platelet-derived endothelial cell growth factor (PD-ECGF) was
initially cloned as a novel non-heparin-binding angiogenic factor
present in platelets (Miyazono et al, 1987; Ishikawa et al, 1989).
Subsequent studies showed that PD-ECGF is a 90 kDa homodimer
and is identical tothymidine phosphorylase (TP)( Barton etal, 1992;
Furukuru et al, 1992; Moghaddam et al, 1992; Usuki et al, 1992).
Transfection of the PD-ECGF/TP gene into transformed fibroblasts
in nude mice results in increased tumour vascularization (Ishikawa
et al, 1989). Stimulation of endothelial cell migration in vitro and
enhancement of tumour growth in vivo have also been reported
(Moghaddam et al, 1995). The precise mechanisms by which PD-
ECGF/TP promotes angiogenesis are unknown. PD-ECGF/TP
hydrolyses thymidine to thymine 2'deoxy-D-ribose-l-phosphate.
In turn, 2'deoxy-D-ribose-1-phosphate is dephosphorylated to 2'
deoxy-D-ribose, which has been shown to be angiogenic in the
chicken-chorioallantoic membrane assay (Haraguchi et al, 1994;
Moghaddam et al, 1995).
PD-ECGF/TP plays an important role in activation of the
commonly used pyrimidine anti-metabolite 5-fluorouracil to
fluorodeoxyuridine (Eda et al, 1993; Sotos et al, 1994). High intra-
cellular levels ofPD-ECGF/TP are related to increased chemosensi-
tivity to 5-fluorouracil. Transfection of KB epidermal or MCF-7
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breast carcinoma cells with the PD-ECGF/TP gene increases
the sensitivity of cells to pyrimidine anti-metabolites (Haraguchi
et al, 1993; Patterson et al, 1995). Moreover, in vitro studies
show that pretreatment of cancer cells with interferon-oc induces
PD-ECGF/TP and enhances 5-fluorouracil-mediated cytotoxicity
(Schwartz et al, 1994). Evaluation of human tumours for PD-
ECGF/TP expression could be of value in predicting response to
fluoropyrimidine-based chemotherapy.
Recent studies have shown that angiogenesis, as assessed by
tumour blood vessel counts, is an important adverse prognostic
factor in non-small-cell lung and breast cancer (Horak et al, 1992;
Giatromanolaki et al, 1996). Since PD-ECGF/TP is reported to be
angiogenic, tumour PD-ECGF/TP expression might also have a
role in defining the clinical course of tumours. This study evalu-
ates PD-ECGF/TP expression in operable non-small-cell lung
cancer and its relation to tumour angiogenesis. Correlation with
tumourhistology, grade, T stage, nodal status and otherparameters
ofprognostic importance, including Ki67, epidermal growth factor
receptor (EGFR) and p53 expression, were also examined. The
prognostic significance of PD-ECGF/TP expression in operable
non-small-cell lung cancer was also assessed.
MATERIALS AND METHODS
Patients and tissues
Surgical resected specimens from 107 patients with operable (Ti,
2-NO, 1 staged) (Mountain, 1986) non-small-cell lung cancer
were used. All patients were treated with surgery alone and had
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survived at least 60 days after operation, to exclude perioperative
mortality-related bias. During follow-up 52 patients had died. The
55 patients alive at the time of the study had been followed up for
a median of45 months (range 3-7 years).
Histological diagnosis, grading and nodal status assessment
were performed on haematoxylin and eosin stained sections. A
total of 69/107 (65%) patients had squamous cell carcinomas and
38/107 (35%) adenocarcinomas. Lymph node involvement was
present in 32/107 (30%) cases. Histological grade I/II was
confirmed in 45 (42%) cases and grade III in 62 (58%).
Ki67, p53 and EGFR immunostaining
Proliferation index was assessed with the monoclonal antibody
Ki67. Frozen material was taken from two separate areas of the
tumour, and the Ki67 assessment was based on the average value.
Three groups were considered based on the percentage of stained
nuclei: 0-10%, low proliferation index (Pil); 10-40%, medium
(Pi2) and >40%, high (Pi3) (Tungekar et al, 1991).
p53 expression was assessed with the CM-1 polyclonal anti-
body on frozen sections with the alkaline phosphatase-anti-alka-
line phosphatase (APAAP) method. Control sections had the
primary antibody omitted. Two groups of nuclear staining were
defined: <10% or weak diffuse staining as negative and >10%
strong staining as positive (McLaren et al, 1992).
Epidermal growth factor receptor (EGFR) was identified by a
murine monoclonal antibody (EGFR1) raised against an epider-
moid carcinoma cell line. Cryostat sections were processed by
means of an indirect immunoperoxidase technique. The positive
control was human placenta and for negative control the primary
antibody was omitted. Two groups were considered: negative or
very weak staining as negative and moderate or positive staining
as positive (Veale et al, 1987).
PD-ECGF/TP immunohistochemistry
PD-ECGF/TP expression was assessed with the P-GF.44C mono-
clonal antibody (Fox et al, 1995). Staining was performed with the
streptavidin-biotin-peroxidase (Dako, UK) technique. Sections
were dewaxed and incubated in 0.5% hydrogen peroxide in
methanol for 30 min. After washing in Tris-buffered saline (TBS),
sections were incubated in normal human serum (1:10) for 20 min.
Sections were then washed with TBS for 5 min and incubated with
the undiluted primary antibody for 30 min. After washing in TBS
for5 min, sections were incubated with biotinylated goat anti-mouse
immunoglobulins (1:200) for 30 min (Dako, UK). After incubation
with streptavidin-biotin complex - horseradish peroxidase (Dako,
UK) for 30 min, the peroxidase reaction was developed using
diaminobenzidine (Sigma Fast tablets) as chromogen, and sections
were counterstained with haematoxylin. Omission of the primary
antibody was used as a negative control. Alveolar macrophages
were used as a positive internal control (Fox et al, 1995).
Tumours were assessed for PD-ECGF/TP expression by the
intensity and extent of staining of cancer cells. Three staining
groups were considered: negative (0-20% of cells stained), weak
(weak diffuse staining intensity or strong intensity in <70% of
cells) and positive (strong staining in more than 70% of cells).
Assessment of vascular grade
Extensive analysis of vascular grade assessment in non-small-cell
lung cancer has been reported in a previous study (Giatromanolaki
et al, 1996). The JC70 monoclonal antibody recognizing CD31
(Parums et al, 1990) was used for microvessel staining on 5-gm
paraffin-embedded sections using the APAAP procedure. Eye
appraisal of immunohistochemically highlighted microvessels and
a Chalkley eyepiece graticule were used to define vascular grades.
For eye appraisal, sections were scaned at low power (x 40 and x
100) and afterwards at x 200, in order to group cases in two
vascular grade categories (low/medium and high). The areas of the
highest vascularization were chosen at low power (x 100) and
Chalkley counting followed on three chosen x 200 fields. The
Chalkley score was the mean value ofthe vessel counts obtained in
these three fields. Two groups were considered: high vascular
grade (Chalkley score, 7-12 vessels within the visual field) and
low/medium vascular grade (Chalkley score, 2-4/5-6). Micro-
vessels adjacent to normal lung were excluded from the appraisal.
The combination of low and medium vascular grade tumours into
one group was based on the results of a previous study on non-
small-cell lung cancer, in which we showed that low and medium
vascular grade cases were associated with node-negative disease
and similar overall survival. High vascular grade tumours had a
poorer survival (P=0.004) and were related to increased nodal
involvement (P=0.0001) (Giatromanolaki et al, 1996).
Intra-and interobserver variability
Both vascular grade and PD-ECGF/TP assessment were examined
for intra- and interobserver variability. Three experienced patholo-
gists assessed the slides separately and repeated the assessment 10
days later. The final decision was taken on a conference microscope.
Statistical analysis
Statistical analysis was performed using the Stata 3.1 Package (Stata
Corporation, Texas, USA). Survival curves were plotted using the
method ofKaplan and Meier (Kaplan and Meier, 1958), and the log-
rank test (Mantel, 1966) was used to determine statistical differences
between life-tables. A Cox proportional hazard model (Cox, 1972)
was used to assess the effects of patient and tumour variables on
overall survival. A chi-square test was used for testing relationships
between categorical tumourvariables. Linearregression analysis was
used to assess intra- and interobserver variability (Altman, 1991).
RESULTS
P-GF.44C invariably stained alveolar macrophages. Alveolar
epithelium was always negative, while bronchiolar epithelium
showed occasional positive reactivity. Bronchial basal and differ-
entiated columnar cells were weakly positive. Weak immunoreac-
tivity was observed in stromal fibroblasts.
Positive PD-ECGF tumour cell reactivity was observed in 27
(25%) cases, weak in 31 (30%) and negative in 49 (46%). High
vasculargrade was observed in 32/107 (30%) cases and low/medium
in 75 (70%).
Intra- and interobserver variability
Intra-observer variability was minimal with the second assessment
correlating with the first for all observers (r-0.89, P<0.008 for
vascular grade and r=0.95, P<0.00I for PD-ECGF/TP). Similarly,
the three investigators' vessel grading and PD-ECGF/TP appraisal
correlated highly with each other (r=0.96, P<0.001 and r=0.95,
P<0.005 respectively).
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Table 1 PD-ECGF expression and correlation with tumour parameters in 107
patients suffering from operable non-small-cell lung cancer
PD-ECGF Expression
Parameter Negative Weak Positive P-value
Vascular grade (VG)
Low/medium 38 24 13 0.01
High 11 7 14
VG (squamous cases)
Low/medium 26 17 5 0.003
High 7 4 10
T stage
Ti 20 18 7 0.04
T2 29 13 20
N stage
NO 36 23 16 0.36
Ni 13 8 11
Histology
Squamous 33 21 15 0.53
Adenocarcinoma 16 10 12
Grade
l/ll 21 14 10 0.81
III 28 17 17
Ki67
Pil 12 11 13
Pi2 26 14 11 0.31
Pi3 11 6 3
EGFR
Negative 9 6 8 0.49
Positive 40 25 19
p53
Negative 24 14 14 0.87
Positive 25 17 13
PD-ECGFITP correlation with angiogenesis
A statistically significant association was found between PD-
ECGF/TP expression and vascular grade (P = 0.01) (Table 1).
Fourteen of 32 (44%) tumours with high vascular grade showed
a positive reactivity for PD-ECGF/TP vs 13/75 (17%) with
low/medium vascular grade disease. The association between posi-
tive PD-ECGF/TP expression and high vascular grade was seen in
the squamous cell tumour subgroup only, in which 10/15 (66%)
cases with positive PD-ECGF/TP expression had a high vascular
grade vs 11/54 (20%) of cases with weak or negative staining
(P=0.001). No significant correlation between PD-ECGF/TP and
vascular grade was found in patients with adenocarcinomas in
which overexpression of PD-ECGF was seen in 4/11 (36%)
patients with high vascular grade tumours and 8/27 (28%) with
low/medium vascular grade tumours (P=0.1). Figure IA and B
show sequential sections ofa squamous cell tumour with high PD-
ECGF/TP expression and high vascular grade.
PD-ECGF/TP correlation with other tumour variables
The relationship of PD-ECGF/TP expression with tumour-related
parameters is shown in Table 1. Positive expression was observed
more frequently in T2-staged cases compared with TI (P=0.04).
Twenty out of 62 (32%) T2 cases showed a positive reactivity vs
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most significant prognostic variables. PD-ECGF/TP expression
did not prove to be of prognostic significance when analysing all
NSCLC patients (P=0.09) or when analysing those patients with
squamous cell tumours (P=0.23) or adenocarcinomas (P=0.31). A
multivariate analysis did not show an independent role for any one
of these tumour parameters in overall survival. This is probably
because ofthe strong association ofangiogenesis with nodal status
and PD-ECGF/TP expression, and of PD-ECGF/TP expression
with T stage.
Kaplan-Meier survival curves for all patients (Figure 2A), NO-
staged (Figure 2B) and Ni-staged cases (Figure 2C) are shown in
Figure 2. Overall survival was not statistically worse for PD-
ECGF/TP-positive cases when all cases were taken into account
(P = 0.09; Figure 2A). However, a statistically significant worse
survival was confirmed for NO-staged patients with positive PD-
ECGF/TP expression (P = 0.04; Figure 2B).
In Figure 3, Kaplan-Meier survival curves are shown for
patients stratified for vascular grade and PD-ECGF/TP expression.
High vascular grade defined a worse prognosis in cases with nega-
tive/weak PD-ECGF/TP expression (P = 0.0001). In cases with
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Figure 2 Kaplan-Meier survival curves with respect to PD-ECGF expression
for all (A), NO-staged (B) and Ni -staged cases (C). -, Negative PD-ECGF
expression; w, weak expression; +, positive/high expression. There was a
significant difference in outcome between combined negative/weak (a/b) and
high PD-ECGF expression tumours (P=0.04) in NO disease
positive PD-ECGF/TP, high or low vascular grade did not show a
significant survival difference.
DISCUSSION
PD-ECGF/TP is a protein with a wide range of activities,
including stimulation ofDNA synthesis (Sotos et al, 1994), angio-
genesis (Moghaddam et al, 1992; Haraguchi et al, 1993) and
endothelial cell migration (Moghaddam et al, 1995). High levels
of PD-ECGF/TP are observed in a variety of human tumours
(Kono et al, 1984; Vertongen et al, 1984; Yoshimura et al, 1990),
and a higher level of serum PD-ECGF/TP is observed in cancer
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Figure 3 Kaplan-Meier survival curves stratified for vascular grade and PD-
ECGF expression. VG UM, low/medium vascular grade; VG H, high vascular
grade; -/w, combined negative and weak PD-ECGF expression tumours; +,
high PD-ECGF expression tumours
patients compared with healthy control patients (Pauly et al,
1977). Apart from neoplastic disorders, angiogenesis plays a crit-
ical role in the pathogenesis of a number of benign diseases, such
as osteo- and rheumatoid arthritis (Brown et al, 1988; Koch et al,
1994). Recent evidence suggests that PD-ECGF/TP plays a role in
the pathogenesis of rheumatoid arthritis through stimulation of
angiogenesis (Takeuchi et al, 1994).
The correlation of PD-ECGF/TP expression in human tumours
with prognostic variables has been evaluated in other tumour
types. Toi et al (1995) showed a statistically significant correlation
of PD-ECGF/TP expression with high vascular grade in breast
cancer. In contrast to these data, Fox et al (1996) failed to show
any relation of PD-ECGF/TP expression with vascular grade in
breast cancer. Moreover, a strong inverse correlation of PD-
ECGF/TP expression with T stage and grade was observed. In a
study on gastric cancer, Maeda et al (1995) found no correlation
between PD-ECGF/TP immunoreactivity and histology, depth of
tumour invasion or nodal involvement.
Heldin et al (1993) studied the PD-ECGF/TP expression in non-
small-cell lung cancer lines. An association was found between
positive expression and well-differentiated cell lines. However, we
demonstrated that a similar relationship was not the case in
surgical specimens from patients with operable non-small-cell
lung cancer. PD-ECGF/TP expression was not related to tumour
grade, nodal status or histology or Ki67, EGFR or p5S3 expression.
We observed a statistically significant direct correlation of PD-
ECGF/TP expression with T stage (P = 0.04). Positive expression
of PD-ECGF/TP was associated with high vascular grade in non-
small-cell lung carcinomas (P = 0.01).
In a previous study, we observed that PD-ECGF/TP expression
in breast cancer was associated with better prognosis in patients
with nodal involvement (Fox et al, 1996), which is in contrast with
our findings in non-small-cell lung cancer. This discrepancy may
be explained by the fact that node-positive breast cancer patients
receive adjuvant chemotherapy including 5-fluorouracil. PD-
ECGF/TP is one of the enzymes involved in the transformation of
5-fluorouracil to metabolites that bind to thymidylate synthase,
resulting in defective DNA synthesis and repair (Sotos et al,
1994). Cells transfected with PD-ECGF/TP have an increased
sensitivity to pyrimidine antimetabolites (Haraguchi et al, 1993;
Patterson et al, 1995). Whether 5-fluorouracil-based adjuvant
chemotherapy would be effective in PD-ECGF/TP-expressing
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non-small-cell lung cancer is unknown. Nonetheless, it may be
worth assessing the anti-tumour activity of 5-fluorouracil and 5-
fluorouracil prodrugs in PD-ECGF/TP-positive non-small-cell
lung cancers.
In conclusion, the results of this study suggest that PD-
ECGF/TP has a role in the pathogenesis of non-small-cell lung
cancer. High expression of PD-ECGF/TP in non-small-cell lung
cancer cells appears to define a more aggressive tumourphenotype
with a poorer prognosis, especially in cases without nodal involve-
ment. This is only partially attributable to the positive correlation
of PD-ECGF/TP expression with high tumoral angiogenesis.
Although the statistically significant association between high
vascular grade and positive PD-ECGF/TP expression cannot prove
a causative correlation, our results further support previous in vitro
observations on the angiogenic role of PD-ECGF/TP in malignant
disease. Vascular grade, together with PD-ECGF/TP expression,
could be of importance in defining groups of patients with poor
prognosis that would benefit from pyrimidine anti-metabolite-
based chemotherapy. These observations may be of clinical value
in designing randomized trials on adjuvant chemotherapy in oper-
able non-small-cell lung cancer.
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